Malaria vaccine based upon the addition of a MSA1 peptide
US6551586B1 · kind B1 · utility
22Cited by
8References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 27, 1998 |
| Grant date | Apr 22, 2003 |
| Priority date | — |
| Expiry date | Nov 27, 2018 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S977/804
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to an expression vector which expresses a malaria MSA1 peptide in combination with a signal peptide and anchor peptide in a host animal. The MSA1 peptide is combined with a signal peptide and anchor peptide for expression. Chimeric peptides being expressed with both signal peptides and anchor peptides were the most effective in eliciting an immunogenic response from a vaccinated host.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.